A multicenter, first-in-human, open-label, phase 1, dose-escalation study to asasess the safety and tolerability and pharmacokinetics of Etirinotecan Pegol in patients with Refractory Solid Tumors
Latest Information Update: 08 Jul 2019
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Advanced breast cancer; Cervical cancer; Colorectal cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
Most Recent Events
- 05 Jul 2019 New trial record